This technology was introduced in

Nature Methods as the method of the year in 2007.[1] In 1975, Sanger first reported the sequencing method by primed synthesis with DNA polymerase.[2] In 1977, epoch-making articles were published in succession. DNA sequencing for the genome of a bacteriophage was conducted with the Sanger enzymatic dideoxy technique based on chain-terminating dideoxynucleotide analogs.[3, 4] A method of DNA sequencing reported in the same year by Maxam and Gilbert and known as Maxam–Gilbert sequencing involves chemical cleavage at specific bases of terminally labeled DNA fragments and separation by gel electrophoresis.[5] The automation of DNA sequence analysis was developed by Caltech (California Institute of Technology, Pasadena, CA, USA) and commercialized by Applied Biosystems (ABI, Applied Biosystems, Foster City, CA, USA), Wilhelm Ansorge at the European Molecular Hydroxychloroquine ic50 Biology Laboratory and Pharmacia-Amersham, later General Electric Healthcare (GE Healthcare, Little Chalfont, Buckinghamshire, UK).[6-8] The Sanger method was used in the first automated fluorescent DNA

sequencing, in which a complete sequence of 57 kb of the human hypoxanthine-guanine MI-503 research buy phosphoribosyltransferase (HGPRT) gene was determined.[9] ABI introduced the ABI Prism 310 automated DNA sequencer in 1996 and the automated capillary sequencer ABI Prism 3700 in 1998. Together with advances in automation and development of new biochemicals, the Sanger method has made possible the determination of various sequences in many research projects. An initial rough draft of the human genome was finished and announced jointly by US President Bill Clinton and British Prime Minister Tony Blair in 2000, and another study reported the sequencing of the human genome of up to 3 billion bases.[10, 11] The first human genome sequence of the Human Genome Project (HGP) was completed in 2003. The HGP

has taken 13 years and cost $US 2.7 billion. Using the basic dideoxy method of Sanger sequencing enabled a great achievement. Before the human genome sequence was completed, Venter proposed a project entitled “The Future of Sequencing: Advancing Towards the $1000 Genome” at the opening session of The Genome Sequencing and Analysis Conference in 2002 and announced that his foundation would earmark a prize for a breakthrough medchemexpress leading to the goal. Formally, the National Institutes of Health convened the National Human Genome Research Institute and introduced the first in a series of $1000 Genome grants designed to advance the development of breakthrough technologies in 2004. The reaction at the completion of the human genome sequence was different between Japanese and US scientists. While Japanese was considered to have “finished” sequence technology, the USA was thought to have begun. Therefore, some venture companies competed to develop new sequence technology.